Full Breakdown
Noah Medical Sets Sights on Hong Kong IPO to Fuel China Expansion
8/28/2026, 11:43:46 AM
Noah Medical Announces Hong Kong IPO Plans
SoftBank-backed surgical-robotics firm Noah Medical disclosed that it will prepare a Hong Kong initial public offering, targeting a raise of more than US $100 million. Founder Zhang Jian said the company intends to file its listing application as early as next year, citing Hong Kong’s status as an international financial centre.
Background and Market Position
Headquartered in the United States, Noah Medical derives roughly 90 % of its revenue from the U.S. market, where its robots have been used in procedures for about 15,000 patients. The firm is backed by SoftBank, positioning it among a wave of high-tech companies seeking capital in Hong Kong’s global exchange.
Expansion Focus on Mainland China
Zhang outlined a strategy to broaden sales of the company’s surgical robots into top-tier and emerging Chinese cities, naming Hangzhou in Zhejiang province as a target. He noted that Sir Run Run Shaw Hospital is a prospective customer following regulatory approval from China’s drug regulator in November of the previous year, and that Prince of Wales Hospital in Hong Kong has already purchased Noah Medical equipment.
Financial Overview
- Funding goal: > US $100 million via Hong Kong IPO (Zhang).
- Revenue composition: ~90 % from U.S. operations (company statement).
- Clinical reach: Robots have treated ~15,000 patients in the United States (company data).
Verbatim Quotes
- “We want to expand our business in [mainland] China, and Hong Kong – as an international financial centre with a globally recognised stock exchange – is the natural choice for our listing,” — Zhang, according to founder — Zhang, founder of Noah Medical.
